Clinical trials: TIA, open to volunteers
Stroke, Stroke (CVA) or TIA
The Imperial Comprehensive Cognitive Assessment in Cerebrovascular Disease (IC3)
Stroke is a major cause of death and disability worldwide, frequently resulting in persistent cognitive deficits among survivors.
- Conditions
- Stroke, Stroke (CVA) or TIA, Dementia, Vascular, Cerebrovascular Disorders
- Trial name
- IC3 (NCT05885295)
- Testing
- MRI brain, Blood tests, cognitive assessments
- Where
- United Kingdom
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Cerebral (CVAs), Ischemic Cerebrovascular Accident
Population-based Brest Stroke Registry
The registry is the main objective exhaustive list of cases validated stroke brain on a geographical area defined to calculate an incidence.
- Conditions
- Cerebral (CVAs), Ischemic Cerebrovascular Accident, Stroke, Brain Ischemia
- Trial name
- BREST (NCT02900521)
- Where
- France
- Volunteers
- 15,000 people
- Sponsor
- University Hospital, Brest
Quality of Life, Stroke, Acute
Cerebrovascular Disease: Quality of Life (CODE: QoL)
The goal of this observational study is to learn about quality of life, stress and caregiver burden in patients with stroke and their caregivers.
- Conditions
- Quality of Life, Stroke, Acute, Sexual Behavior, Stress
- Trial name
- CODE:QoL (NCT06443268)
- Testing
- questionnaire, hair samples, blood samples, clinical exam
- Where
- Switzerland
- Volunteers
- 680 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Stroke, Transient Ischemic Attack
Smartwatch-Guided Secondary Prevention After Stroke
After a first stroke or transient ischemic attack (TIA), the risk of recurrence is high in the weeks and months following the initial event.
- Trial name
- WATCH-STEP (NCT07640360)
- Testing
- Smartwatch-Guided Secondary Prevention after Stroke
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Brest
Stroke, Acute Ischemic, Intracerebral Hemorrhage
The Stroke Aetiology and VascuLar Disease in Stroke and TIA Study - A Clinical Study Analysing the Effects on Cardiovascular Health and Disease With an Extended Investigation Into Conditions Causative of Stroke and Concomitant Cardiovascular Disease in Patients Admitted for Acute Stroke or TIA
Annually, about 4000 Swedes suffer a recurrent stroke, and for many, their lives change dramatically. To prevent recurring strokes, knowledge about the individual's risk of recurrence is needed to tailor an effective preventive…
- Conditions
- Stroke, Acute Ischemic, Intracerebral Hemorrhage, TIA, Hypertension
- Trial name
- SALSA (NCT07491744)
- Testing
- Extended assessment
- Where
- Sweden
- Volunteers
- 600 people
- Sponsor
- Region Stockholm
Stroke (CVA) or TIA
Stroke Care During the COVID-19 Pandemic
Background: The SARS-CoV-2 pandemic led to substantial changes in the allocation of healthcare resources and affected the behavior of patients experiencing stroke symptoms.
- Trial name
- NCT07795021
- Testing
- statistical analysis
- Where
- 4 sites in Czechia, Germany and 2 more
- Volunteers
- 40,000 people
- Sponsor
- Dr. Yaroslav Winter
Stroke, TIA
Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
An observational study to determine if individuals with increased platelet FcyRIIa will have a higher risk of ischemic events.
- Conditions
- Stroke, TIA, Ischemic Stroke, Ischemic
- Trial name
- FCG (NCT05518305)
- Testing
- Medical Imaging
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Stroke Acute, Atrial Fibrillation
Stroke Alarm Efficacy Trial
The aim of this study is to test the efficacy of the CE-marked wearable system Stroke Alarm to identify the onset of a stroke with unilateral arm motor deficit within 3 hours of onset.
- Conditions
- Stroke Acute, Atrial Fibrillation, TIA
- Trial name
- StrokeAlarmEFF (NCT06315192)
- Testing
- Stroke Alarm
- Where
- 10 sites in Sweden
- Volunteers
- 500 people
- Sponsor
- Region Skane
Stroke
Post-Stroke Secondary Prevention With Digital Monitoring
Stroke is the second leading cause of death and a major cause of disability worldwide. In 2019, Disability-Adjusted Life-Years (DALYs) related to stroke was estimated to have reached 143 million.
- Trial name
- PSDM (NCT06837311)
- Testing
- Ecological Momentary Assessment (EMA), Biological assessment, Psychological examination and Substance Use symptomatology
- Where
- France
- Volunteers
- 388 people
- Sponsor
- University Hospital, Bordeaux
Atrial Fibrillation, Stroke, Ischemic
Echocardiographic Predictors of Atrial Fibrillation
This prospective study aims to identify the diagnostic accuracy of echocardiographic predictors of atrial fibrillation in patients with ESUS (embolic stroke of undetermined source) or TIA (transient ischemic attack).
- Conditions
- Atrial Fibrillation, Stroke, Ischemic, Embolic Stroke of Undetermined Source, TIA, Brain
- Trial name
- EPAF-7 (NCT05044208)
- Testing
- ECG monitoring
- Where
- Austria
- Volunteers
- 200 people
- Sponsor
- Karl Landsteiner University of Health Sciences
Ischemic Stroke, Transient Ischemic Attack
Empowerment and Mobile Technology in the Control of Cardiovascular Risk Factors in Patients With Ischemic Stroke
The CARDIOSTROKE is a randomized trial comparing mobile-device assisted control of hypertension together with screening of occult atrial fibrillation to standard care in patients with recent ischemic stroke or transient ischemic…
- Conditions
- Ischemic Stroke, Transient Ischemic Attack, Atrial Fibrillation, Hypertension
- Trial name
- CARDIOSTROKE (NCT03710902)
- Testing
- ECG monitoring for 3 weeks, Self-monitoring of BP and self-titration of antihypertensive medication
- Where
- 4 sites in Finland
- Volunteers
- 405 people
- Sponsor
- Jukka Putaala
Ischemia Stroke, TIA (Transient Ischemic Attack)
Upfront Lipid-Lowering Therapy With Statins Combined With Hybutimibe in Patients With Acute Ischemic Stroke or Transient Ischemic Attack.
This study aims to evaluate whether an upfront combination lipid-lowering therapy (statins combined with hybutimibe) can further improve the 8-week LDL-C target achievement rate (<1.8 mmol/L and ≥50% reduction from baseline)…
- Trial name
- NCT07908875
- Testing
- Atorvastatin, Hybutimibe 10mg QD
- Volunteers
- 520 people
- Sponsor
- First Affiliated Hospital of Wannan Medical College